Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published 6 June 2008 Volume 2008:2(2) Pages 377—388

DOI https://doi.org/10.2147/OPTH.S1485

M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment

Yeh S, Chan-Kai BT, Lauer AK

Clinical Ophthalmology 2011, 5:1249-1256

Published Date: 1 September 2011

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA

Yao C, Tai Z, Wang X, Liu J, Zhu Q, Wu X, Zhang L, Zhang W, Tian J, Gao Y, Gao S

International Journal of Nanomedicine 2015, 10:3403-3416

Published Date: 8 May 2015

Risk factors for progression to blindness in high tension primary open angle glaucoma: Comparison of blind and nonblind subjects

Karanjit S Kooner, Mohannad AlBdoor, Byung J Cho, Beverley Adams-Huet

Clinical Ophthalmology 2008, 2:757-762

Published Date: 5 December 2008

Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid

Lawrence Y Ho, Larissa Camejo, Malik Y Kahook, Robert Noecker

Clinical Ophthalmology 2008, 2:769-772

Published Date: 5 December 2008

Vision loss associated with the use and removal of intraocular silicone oil

Patrick D Williams, Christopher G Fuller, Ingrid U Scott, Dwain G Fuller, Harry W Flynn Jr

Clinical Ophthalmology 2008, 2:955-959

Published Date: 5 December 2008

Primary localized conjunctival amyloidosis: A case report with a ten-year follow-up period

Juan Carlos Mesa-Gutiérrez, Tomás Martí Huguet, Noemí Barnils Garcia, Jorge Arruga Ginebreda

Clinical Ophthalmology 2008, 2:685-687

Published Date: 12 September 2008

SUNCT syndrome: The materialization of a headache syndrome

Ottar Sjaastad

Clinical Ophthalmology 2008, 2:533-543

Published Date: 12 September 2008

Optic nerve sheath fenestration in cryptococcal meningitis

Tatyana Milman, Neena Mirani, Roger E Turbin

Clinical Ophthalmology 2008, 2:637-639

Published Date: 12 September 2008

Age and disease-related structural changes in the retinal pigment epithelium

Vera L Bonilha

Clinical Ophthalmology 2008, 2:413-424

Published Date: 6 June 2008

Micropulse diode laser trabeculoplasty (MDLT): A phase II clinical study with 12 months follow-up

Antonio Maria Fea, Alex Bosone, Teresa Rolle, Beatrice Brogliatti, Federico Maria Grignolo

Clinical Ophthalmology 2008, 2:247-252

Published Date: 6 June 2008